Open-label Study of Adjunctive GNX Treatment in Children & Adults With

See also
Status	Clinical Trial	Phase
Completed	`NCT04595513` - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants	Phase 1/Phase 2
Completed	`NCT02687633` - Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex	N/A
Completed	`NCT02201212` - Everolimus for Cancer With TSC1 or TSC2 Mutation	Phase 2
Completed	`NCT01767779` - Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC
Recruiting	`NCT05104983` - Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study	Phase 2
Recruiting	`NCT02098759` - Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex	N/A
Recruiting	`NCT01730209` - Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex	Phase 2/Phase 3
Recruiting	`NCT03356769` - Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex	Phase 2
Recruiting	`NCT04987463` - Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants	Phase 2/Phase 3
Completed	`NCT05323370` - Lymphangioleiomyomatosis, a Study on Cathepsin K
Completed	`NCT03276195` - Studies in Patients With Tuberous Sclerosis Complex
Recruiting	`NCT05059327` - Basimglurant in Children, Adolescents, and Young Adults With TSC	Phase 2
Completed	`NCT02061397` - Safety of Simvastatin in LAM and TSC	Phase 1/Phase 2
Active, not recruiting	`NCT04112537` - Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
Active, not recruiting	`NCT02962414` - Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment	Phase 3
Active, not recruiting	`NCT05495425` - Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC	Phase 3
Recruiting	`NCT05044819` - Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution	Phase 4
Completed	`NCT01929642` - Rapalogues for Autism Phenotype in TSC: A Feasibility Study	Phase 2
Recruiting	`NCT06160310` - Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
Recruiting	`NCT05534672` - Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex	Phase 3

NCT number	NCT05604170
Study type	Interventional
Source	Marinus Pharmaceuticals
Contact
Status	Enrolling by invitation
Phase	Phase 3
Start date	May 16, 2022
Completion date	June 2027

Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms